AL BLUNT, MD

Hainesport, NJ 08036 | 609-647-8919 | algblunt@gmail.com | www.linkedin.com/in/algblunt

Oncologist and Drug Development Expert

Deep knowledge and broad experience in drug development, including the scientific principles of drug development, regulatory strategy, and all aspects of study design, execution, and analysis. Extensive experience with phases I to III studies. Experience with a wide range of solid tumors and hematologic malignancies and drug classes. Strong background of successfully working with multifunctional teams to achieve drug development goals.

Skills

Strategic thinker | effective communicator | strong leader & motivator | engaged mentor | insightful trainer | skilled presenter

Therapeutic Experience - Cancer Type

Breast cancer | cervical cancer | colorectal cancer | hepatocellular carcinoma | kidney cancer | lung cancer ovarian cancer | pancreatic cancer | prostate cancer | acute lymphocytic leukemia | acute myeloid leukemia |chronic lymphocytic leukemia | chronic myeloid leukemia | multiple myeloma | myelodysplastic syndrome |non-Hodgkin lymphomas

Therapeutic Experience - Drug Class

Antibody-drug conjugates | bioengineered bacteria | CAR T cell therapy | checkpoint inhibitors | cytotoxic chemotherapy | gene therapy | hormonal therapies | monoclonal antibodies | oncolytic viruses radiopharmaceuticals | therapeutic vaccines | tyrosine kinases inhibitors & other targeted therapies

PROFESSIONAL EXPERIENCE

PRECISION FOR MEDICINE (Precision) | Gladstone, New Jersey **April 2019 - May 2024**

Global CRO with a focus on the development of precision medicine-based therapeutics.

Senior Vice President, Global Medical: June 2021 - May 2024

Senior Vice President, Medical – Americas: April 2019 - May 2021

- Served as a hematology-oncology subject matter expert in support of Precision's goals.
- Provided strategic drug development consulting to oncology and rare disease clients.
- Provided medical and scientific expertise to project teams for ongoing projects in phases 1, 2, and 3.
- Provided oversight and leadership globally for Medical Science, Global Safety, and Clinical Science, with up to 10 direct reports and more than 40 indirect reports.
- Responsibilities included managing direct reports, ensuring adequate resources to meet the needs of clients, providing support and guidance for strategic goals and overall growth, and managing escalated issues.
- Supported business development activities globally to drive new business and enhance relationships, including client engagement, proposals support, bid defense meetings, client capabilities meetings, and through attendance at professional meetings.
- Served as a member of the Clinical Solutions senior leadership team, providing input on strategic business decisions and driving scientific and medical strategy to achieve business goals.
- Developed training modules and conducted company-wide training on indications, drugs, and concepts.

ADVAXIS IMMUNOTHERAPIES | Princeton, New Jersey **March 2017 - October 2018**

Biotech company with a novel cancer immunotherapy platform based on bioengineered bacteria.

Vice President, Medical

- Integrated key strategic and medical input from senior management, research staff, and external medical advisors into clinical development strategy and execution for Advaxis' portfolio.
- Led the development of solutions to multiple critical challenges.
- Developed trial protocols and provided medical oversight for clinical trials.
- Collaborated with strategic partners and key opinion leaders.
- Interacted with the FDA regarding regulatory filings and clinical aspects of ongoing programs.
- Managed direct reports.

COVANCE, INC. | Princeton, New Jersey **September 1998 - February 2017**

Large global full service CRO

Associate Medical Director to Executive Medical Director

Lead oncology physician for Covance in the Americas working with a wide range of biotech, mid-size pharma, and large pharma companies.

- Provided medical monitoring of oncology clinical trials globally in phases 1 to 3.
- Provided subject matter expertise and consultation to project teams and senior leaders.
- Provided medical and scientific leadership to support business development and contributed to Covance's growth and success as a CRO leader.
- Provided strategic consulting to clients.
- Consulted with thought leaders in oncology.
- Wrote clinical development plans and clinical trial report content.
- Developed and delivered company-wide immuno-oncology training.

EDUCATION & PROFESSIONAL DEVELOPMENT

Fellowship in Pediatric Hematology/Oncology, Washington University School of Medicine and St. Louis Children's Hospital

Residency in Pediatrics, Children's Hospital of Philadelphia

Doctor of Medicine, University of Pennsylvania School of Medicine

Bachelor of Science, Biochemistry, City College of the City University of New York, New York, NY

MEMBERSHIPS

American Society of Clinical Oncology
American Society of Hematology
European Society of Medical Oncology
Sigma Xi, the Scientific Research Society
Society for the Immunotherapy of Cancer
Society of Salk Scholars.

HONORS

- Jonas Salk Award, City College of New York

- American Cancer Society Clinical Fellowship, Washington University
- Howard Hughes Medical Institute Postdoctoral Fellowship for Physicians Award, Washington University
- Covance Way Award, Covance
- We're All in Sales Award, Covance.

PUBLICATIONS AND PRESENTATIONS

1. Precision for Medicine/Fierce Biotech Webinar: Multiple Myeloma Insights From KOL Investigators. Paul G. Richardson, MD; Maria-Victoria Mateos, MD; Leah Tasca, Al Blunt, MD. March 2021
2. Precision for Medicine/Applied Clinical Trials Webinar: Harnessing CAR-T Therapy for Hematologic Malignancies and Solid Tumors: Experience from City of Hope. Elizabeth Budde, MD; Saul Priceman, Ph.D.; Al Blunt, MD. June 24, 2020
3. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Melisi D, Garcia-Carbonero R, Macarulla T Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Tabernero J. Br J Cancer, 2018 vol. 20 p. 6660
4. Addressing Immunotherapy Drug Development Challenges. Frank Makosiej and Al Blunt. Clinical Leader, May 04, 2017
5. International Society for Pharmacoeconomics and Outcomes Research 21st Annual Meeting (Abstract PMD85). Trends in Prostate Cancer Screening Before and After Publication of US Preventive Services Task Force Draft Guidelines: An Analysis of Data from a Large US Laboratory Service Provider Wahl PM, Timmerman J, Mammone V, Blunt AG, Anastassopoulos KP. May 25, 2016, Washington D.C.
6. ASCO Gastrointestinal Cancers Symposium (January 21-23, 2016). Abstract #159750 A randomized phase 2, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with advanced or metastatic unresectable pancreatic cancer (PC). Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Martin Fuchs, Jorg Trojan, Helmut Oettle, Mark Kozloff, Ann Cleverly, Ivelina Gueorguieva, Durisala Desaiah, Michael M. F. Lahn, Al Blunt, Karim A. Benhadji, Josep Tabernero
7. Covance Therapeutic Area Blog. The Remarkable Rebirth of Cancer Immunotherapy. August 2015
8. Business Review Webinar. Pragmatic Solutions for Immuno-Oncology Clinical Trial Programs May 21, 2015
9. ASCO Annual Meeting 2013. Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer. Mark Kozloff, Rocio Carbonero, Tamara Nadal, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. F. Lahn, Sada Pillay, Al Blunt, Josep Tabernero, Teresa Macarulla; J Clin Oncol 31, 2013 (suppl; abstr 2563)
10. Fierce Biotech Webinar. Beyond MTD: Phase I Oncology Protocol Design for Targeted Therapies March 9, 2011
11. Drug Information Association Annual Meeting 2006. Premises, Paradigms, and Paradoxes in Oncology Drug Development June 18 – 22; Philadelphia, PA.
12. Sharing Best Practices in Oncology Clinical Trials. Phase I Study Design. November 18, 2003, Cambridge, MA.
13. SCBA/BIOPHARM 2003 Annual Conference. From Bench top to Bedside: Key Issues in the Early Development of Anti-cancer drugs November 8th and 9th, 2003 Rutgers University, Rutgers Busch Center, 604 Bartholomew Rd, Piscataway, NJ 08854-8002
14. Greene, J.M., Li, Y.L., Yourey, A., Gruber, J., Carter, K.C., Shell, P.A., Florence, D.R., Duan, D.R., Blunt, A.G., Ornitz, D.M., Ruben, S.M.., and Alderson, R.F. Identification, and characterization of a new member of the fibroblast growth factor family. (1998) Eur. J. Neurosci. 10 (5): 1911-1925.

15. Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. Blunt, A.G., Lawshé, A., Cunningham, M.L., Seto, M.L., Ornitz, D.M., MacArthur, C.M. (1997) J. Biol. Chem. 272 (6) 3733-3738.